Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals announced that the first patient has been dosed in the global, phase 3 LUGANO clinical trial of Duravyu, formerly EYP-1901, as a treatment for wet age-related macular degeneration, according to a press release.

CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.

BARCELONA, Spain — A subgroup analysis of the DAVIO 2 trial showed that eyes implanted with the EYP-1901 intravitreal insert maintained stable visual acuity with strong anatomic control over 8 months, according to a presenter.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA, speaks about 4D-150, a novel intravitreally administered gene therapy for wet age-related macular degeneration.

A phase 2b clinical trial of CLS-AX, a tyrosine kinase inhibitor under evaluation for the treatment of wet age-related macular degeneration, achieved its primary and secondary outcomes, according to a Clearside Biomedical press release.

In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute discusses how tyrosine kinase inhibitors differ from other treatment options for retinal diseases.

In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, of Retina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.

In this Healio Video Perspective from the Retina Society meeting, Pravin U. Dugel, MD, of Ocular Therapeutix shares positive updates on studies investigating Axpaxli, an axitinib implant for the treatment of retinal diseases.

AiViva Biopharma announced that it has completed enrollment and dosing of the last patient in a phase 1 clinical trial of AIV007 for wet age-related macular degeneration and diabetic macular edema.